Advertisement

Thoraxtumoren pp 460-469 | Cite as

Nichtoperative Behandlung primärer und sekundärer Pleuratumoren

  • C. Manegold
  • P. Schraube
  • H. Bischoff

Zusammenfassung

Das Mesotheliom ist der häufigste primäre Pleuratumor. Gleichwohl gehören die malignen Mesotheliome zu den selteneren Tumorerkrankungen (Weiss u. Muggia 1979; Aisner u. Wiernik 1978). Als bedeutendster ätiologischer Faktor für die Entwicklung maligner Mesotheliome gilt die Asbestexposition (Taryle et al. 1962; Cochrane u. Webster 1978; Legha u. Muggia 1977; Whitewell u. Raw-cliffe 1971). Es handelt sich um aggressiv wachsende Tumoren. Die mediane Überlebenszeit unbehandelter Patienten beträgt ca. 12 Monate (Legha u. Muggia 1977 a; Aisner u. Wiernik 1981; Alberts et al. 1988).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aisner J, Wiernik PH (1978) Malignant mesothelioma. Current status and future prospects. Chest 74: 438–444PubMedCrossRefGoogle Scholar
  2. Aisner J, Wiernik PH (1981) Chemotherapy in the treatment of malignant mesothelioma. Semin Oncol 8: 335–343PubMedGoogle Scholar
  3. Alberts AS, Falkson G, Goldhals L, Vorobiof DA, van der Merwe CA (1988) Malignant pleural mesothelioma: a disease unaffected by current therapeutic manoeuvres. JCO 6/ 3: 527–535Google Scholar
  4. Baldini EH, Recht A, Strauss GM et al. (1997) Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63: 334–338PubMedCrossRefGoogle Scholar
  5. Ball DL, Cruickshank DG (1990) The treatment of malignant mesothelioma of the pleura: review of a 5 year experience, with special reference to radiotherapy. Am J Clin Oncol: 13: 4–9PubMedCrossRefGoogle Scholar
  6. Belani CP, Herdon J, Vogelzwang NJ, Green MR (1994) Edatrexate for malignant mesothelioma: A phase II-study of the Cancer and Leukemia Group B. Proc ASCO 13 /339: 1087Google Scholar
  7. Bischoff HG, Branscheid D, Probst G (1991) Chirurgische Therapie beim malignen Pleuraerguß. Z Herz Thorax Gefäßchir 5: 173–177Google Scholar
  8. Bissett D, Macbeth FR, Cram I (1991) The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol (R Coll Radiol) 3: 315–317CrossRefGoogle Scholar
  9. Boutin C, Cagnino P, Viallat JR (1980) Thoracoscopy in the early diagnosis of malignant pleural effusions. Endoscopy 12: 155PubMedCrossRefGoogle Scholar
  10. Boutin C, Rey F, Viallat JR (1995) Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 108: 754–758PubMedCrossRefGoogle Scholar
  11. Branscheid D, Bischoff H, Vogt-Moykopf I (1988) Chirurgie der malignen Pleuraergüsse einschließlich des malignen Pleura-Mesothelioms. In: Hossfeld DK, Gatzenmeier U (Hrsg) Maligne Ergüsse. Karger, Basel ( 33, S 81–97 )Google Scholar
  12. Butchart E, Ashcroft T, Barnsley W, Holden M (1976) Pleuropneomonectomy in the management of diffuse malignant mesothelioma of the pleura. Thorax 31: 15–24PubMedCrossRefGoogle Scholar
  13. Cochrane JC, Webster J (1978) Mesothelioma in relation to asbestos fiber exposure. A review of 70 serial cases. South Afr Med J 54: 279–281Google Scholar
  14. Colbert N, Vannetel IM, Izrael V et al. (1985) A prospective study of etorubicin in malignant mesothelioma. Cancer 56: 2170–2174PubMedCrossRefGoogle Scholar
  15. Dabouis G, Lemevel B, Corroler J (1981) Treatment of diffuse pleural malignant mesothelioma by disdichlorodiamineplatinum (CDDP) in nine patients. Cancer Chemother Pharmacol 5: 209–210PubMedCrossRefGoogle Scholar
  16. Duhin JT (1969) Solitary rhabdomyosarcoma of the pleura. Report of a case with a note on the nomenclature of pleura tumors. J Thorax Cardiovasc Surg 37: 236–241Google Scholar
  17. Eisenhauer EA, Evans WK, Raghaven D et al. (1986) Phase II stuay of mitoxantrone in patients with mesothelioma: A National Cancer Institute of Canada Clinical Trials Group study. Cancer Treat Rep 70: 1029–1030PubMedGoogle Scholar
  18. Eimes PC, Simpson MJC (1976) The clinical aspects of mesothelioma. Q J Med 45: 427–449Google Scholar
  19. Fentiman IS, Millis R, Sexton S, Hayward JL (1981) Pleural effusion in breast cancer. Cancer 47: 2087–2092PubMedCrossRefGoogle Scholar
  20. Frank W, Großer H, Mai J, Loddenkemper R (1989) Pleurodese mit Tetracyclin-Hydro-chlorid. Pneumologie 43: 80–84PubMedGoogle Scholar
  21. Gupta RK, Paolini FA (1967) Liposarcoma of the pleura, report of a case with a review of the literature and views on histogenesis. Am Rev Respir Dis 95: 298–304PubMedGoogle Scholar
  22. Hausheer FH, Yarbo JW (1985) Diagnosis and treatment of malignant pleural effusion. Semin Oncol 12: 54–75PubMedGoogle Scholar
  23. Henß H, Fiebie HH, Schildge J, Arnold H, Hass J (1988) Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie II: 118–120Google Scholar
  24. Hilaris BS, Dattatreyudu N, Kwong E, Kutcher GK, Martini N (1984) Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 10: 325–331PubMedCrossRefGoogle Scholar
  25. Kirmani S, Cleory SM, Mowry J, Hawell SB (1988) Intracavitary cisplatin for malignant mesothelioma; an update. Proc ASCO 7: 273Google Scholar
  26. Kreuser ED, Seyfried E, Hartmann R, Schreml W, Rasche U (1984) Behandlung maligner Pleuraergüsse durch Fibrinklebung. Tumor Diagn Ther 5: 55–58Google Scholar
  27. Kutcher GJ, Kestler C, Greenblatt D, Brenner H, Hilaris BS, Nori D (1987) Technique for external beam treatment for mesothelioma. Int J Radiat Oncol Biol Phys 13: 1747–1752PubMedCrossRefGoogle Scholar
  28. Law MR, Gregor A, Hodson ME, Bloom HJG, Turner-Warwick M (1984) Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax 39: 255–259PubMedCrossRefGoogle Scholar
  29. Legha S, Muggia FM (1977 a) Therapeutic approaches to malignant mesothelioma. Cancer Treat Rev 4: 13–25PubMedCrossRefGoogle Scholar
  30. Legha S, Muggia FM (1977 b) Pleural mesothelioma: clinical features and therapeutic implications. Ann Intern Med 87: 613–621PubMedGoogle Scholar
  31. Lerner HJ, Schoenfeld DA, Martin A, Falkson G, Borden E (1983) Malignant mesothelioma, the Eastern Cooperative Oncology Group (ECOG) experience. Cancer 52: 1981–1985PubMedCrossRefGoogle Scholar
  32. Linden CJ, Mercke C, Albrechtsson U, Johansson L, Ewers SB (1996) Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study. Eur Respir J 9: 2565–2572PubMedCrossRefGoogle Scholar
  33. Magri MD, De Giovanni D, Serra C et al. (1988) Epirubicin treatment of mesothelioma: A phase-II study. Proc ASCO 7: 207Google Scholar
  34. Marley MRS (1979) Malignant pleural effusions and their treatment by intercostal tale pleurodesis. Br J Dis Chest 73: 173–177CrossRefGoogle Scholar
  35. Martini N, Bains MS, Beattie EJ (1975) Indications for pleurectomy in malignant effusion. Cancer 35: 734PubMedCrossRefGoogle Scholar
  36. Meerbeck J van, Debruyne C, Postmus PE, Groen HJM, Manegold C et al. (1996) Sequential phase II studies with paclitaxel and gemcitabine in malignant pleural mesothelioma. Eur Res J 9 (Suppl 23) 400 s: 2513Google Scholar
  37. Mintzer DM, Nelsen D, Frinner D, Meelan R, Gralla R (1985) Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 69: 711–712PubMedGoogle Scholar
  38. Moore M, Andersen J, Burris H et al. (1995) A randomized trial of gemcitabine vs. 5-FU as first-line therapy in advanced pancreatic cancer. Proc ASCO 14: 1099, 473Google Scholar
  39. Müsch E, Paar WD, Hoffmann B et al. (1989) Intrapleurale Instillation von Mitoxantron zur Palliativtherapie maligner Pleuraergüsse. Tumor Diagn Ther 10: 64–71Google Scholar
  40. Ong ST, Vogenzwang NJ (1996) Current therapeutic appraoches to unresectable (primary and recurrent) disease. In: Aisner J, Arriagada R, Green MR, Martini N, Perry MC (eds) Comprehensive textbook of thoracic oncology, zz, Baltimore, pp 799–812Google Scholar
  41. Ostrowski MJ (1989) Intracavitary therapy with Bleomycin for the treatment of malignant pleural effusions. J Sure Oncol (Suppl I ): 7–13Google Scholar
  42. Pfeifle CE, Howell SB, Markman M (1985) Intracavitary cisplatin chemotherapy for mesothelioma. Cancer Treat Rep 69: 205–207PubMedGoogle Scholar
  43. Roberts GH (1976) Distant with drawl metastases in pleural mesothelioma. Br J Dis Chest 70: 246–250PubMedCrossRefGoogle Scholar
  44. Salver WR, Eggleston JC, Erozan YS (1975) Efficacy of pleural needle biopsy and pleural fluid cytopathology in the diagnosis of malignant neoplasm involving the pleura. Chest 67: 536CrossRefGoogle Scholar
  45. Samson MK, Wasser LP, Borden EC et al. (1987) Randomized comparison of cyclophosphamide, imidazole carboxamied, and adriamycin vs. cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: A Sarcoma Inter-group Study. JCO 5 /1: 86–91Google Scholar
  46. Sauer H, Kremer G, Wilmanns W (1987) Zur Toxizität einer CYVADIC-Modifikation bei Patienten mit Weichteilsarkomen oder malignen Mesotheliomen. Onkologie 10: 294–300PubMedCrossRefGoogle Scholar
  47. Sauter ER, Langer C, Coia LR, Goldberg M, Keller SM (1995) Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation. J Surg Oncol 60: 100–105PubMedCrossRefGoogle Scholar
  48. Selikoff IY, Churg J, Hammond FC (1965) Relations between exposure to asbestos and mesothelioma. N Engl J Med 272: 560–565PubMedCrossRefGoogle Scholar
  49. Shuman LS, Libshutz HI (1984) Pictorial essay. Solid pleural manifestations of lymphoma. AJR 142: 269–273PubMedGoogle Scholar
  50. Solheim OP, Saeter G, Finnanger AM (1992) High dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 65: 956–960PubMedCrossRefGoogle Scholar
  51. Sörensen PG, Bach F, Bork E, Hansen HW (1985) Randomized trial of doxorubicin vs. cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 69: 1431–1432PubMedGoogle Scholar
  52. Soubra M, Dunscombe PB, Hodson DI, Wong G (1990) Physical aspects or external beam radiotherapy for the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 18: 1521–1527PubMedCrossRefGoogle Scholar
  53. Sugarbaker DJ, Garcia JP, Richards WG et al. (1996) Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 224: 288–94PubMedCrossRefGoogle Scholar
  54. Taryle DA, Lakshininarayan S, Sahn SA (1962) Pleural mesotheliomas — an analysis of 18 cases and review of the literature. Medicine 55: 153–162CrossRefGoogle Scholar
  55. Vogelzwang NJ, Goutson M, Graziano S, Aisner J, Cooper MR, Modeas C, Green MR (1989) Carboplatin in malignant mesothelioma. A phase II-study of the CALGB. Proc ASCO 8: 321Google Scholar
  56. Vogelzwang NJ, Herndorn J, Clamon GH, Maurer AM, Cooper MR, Green MR (1994) Paclitaxel (Taxol) for malignant mesothelioma: a phase II-study of the Cancer and Leukemia Group B (CALGB 9234) (Abstr). Proc ASCO 13: 405Google Scholar
  57. Wagner JC (1965) Epidemiology of diffuse mesothelial tumors: Evidence of an association from studies in South Africa and United Kingdom. Ann NY Acad Sci 132: 575–578PubMedCrossRefGoogle Scholar
  58. Weiss RB, Muggia FM (1979) Working conference on mesothelioma treatment trials. Cancer Res 33: 799 - 800Google Scholar
  59. Whitewell F, Rawcliffe RM (1971) Diffuse malignant pleura mesothelioma and asbestos exposure. Thorax 26: 6–22CrossRefGoogle Scholar
  60. Winkelmann M, Pfitzer P (1981) Blind pleural biopsy in combination with cytology of pleural effusions. Acta Cytol (Baltimore) 25: 373Google Scholar
  61. Yang HY, Weaver LI, Foti PR (1983) Primary malignant fibrous histiocytoma of the pleura. Acta Cytol (Baltimore) 27: 683–687Google Scholar
  62. Zafoznik AJ, Oswald SG, Langin M (1983) Intrapleural tetracycline in malignant pleural effusions. Cancer 51: 752–755CrossRefGoogle Scholar
  63. Zidar B, Bugh R, Schiffer L, Raju R, Vaidya K, Home D, Baker L (1983) Treatment of 6 cases of mesothelioma with doxorubicin and cisplatinum. Cancer 52: 1788–1791PubMedCrossRefGoogle Scholar

Copyright information

© Springer Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • C. Manegold
  • P. Schraube
  • H. Bischoff

There are no affiliations available

Personalised recommendations